Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL LOW CALCIUM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIANEAL LOW CALCIUM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER vs DIANEAL LOW CALCIUM W/DEXTROSE 4.25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dialysis solution containing dextrose and electrolytes; dextrose provides osmotic gradient for ultrafiltration and caloric supplementation, while electrolytes maintain acid-base and electrolyte balance in peritoneal dialysis.
Sterile, nonpyrogenic, hyperosmotic solution containing dextrose as osmotic agent; creates osmotic gradient across peritoneal membrane to remove excess fluid and waste products via diffusion and ultrafiltration.
Intravenous infusion, 500-2000 mL per day as maintenance fluid; rate adjusted based on clinical status, typically 1-2 mL/kg/hour in adults.
Intraperitoneal administration: 2 liters per exchange, 4 exchanges daily, with dwell times of 4-6 hours; dextrose concentration adjusted to achieve ultrafiltration goals.
None Documented
None Documented
Terminal half-life: 2.5–3.5 hours. Clinically, this allows for rapid clearance; accumulation may occur in renal impairment.
Not applicable for intraperitoneal dextrose; systemic glucose half-life ~1.5-3 h in normal metabolic state. Peritoneal dialysis of dextrose reflects continuous absorption and metabolism.
Renal: >95% as unchanged drug and metabolites. Biliary/fecal: <5%.
Peritoneal elimination; glucose absorbed systemically is metabolized via glycolysis, with <5% excreted unchanged in urine. Dextrose removal relies on diffusion into dialysate; net ultrafiltrate exits via peritoneal catheter.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution